Drug recall · March 12, 2014
Teva Hydroxyzine Pamoate Capsules recall
Why: CGMP Deviations: Hydroxyzine Pamoate Capsules, USP, 25 mg were manufactured using an unapproved material: API was incorrectly released for use in manufacturing.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Teva Hydroxyzine Pamoate Capsules, USP, 25 mg, 100- count bottle, Rx Only,Distributed by Teva Pharmaceuticals, USA, Sellersville, PA. NDC 0555-0323-02.
- Lots / codes
Lot # 34016752A, Exp. 09/16. Lot # 34016753A, Exp. 09/16.
- Quantity
- 35746 capsules
- Company
- Teva Pharmaceuticals USA, Horsham, PA
- Distribution
- Nationwide.
- Initiated
- January 24, 2014 · Voluntary: Firm initiated
- Classified
- February 28, 2014
- Reported
- March 12, 2014
- Ended
- October 8, 2014
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Hydroxyzine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.